Skip to main content
Premium Trial:

Request an Annual Quote

Marina Says microRNA Antagonists Effective in In Vivo Testing

Premium

Marina Biotech this week announced that it has conducted experiments in which its conformationally restricted nucleotide technology was used to produce microRNA antagonists capable of de-repressing targets of miR-122 in vivo.

The agent could trigger two-and-a-half-fold de-repression of the miRNA's targets at a dose of 10 mg/kg, while demonstrating “good tolerability with repeat dosing,” the company said.

The CRN technology essentially comprises nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked. Marina has been touting its utility in the creation of efficient miRNA inhibitors for some time (GSN 7/14/2011).

"With the completion of this early work with our CRN chemistry, we now have in vivo demonstration of our ability to develop single-stranded oligonucleotide therapeutic compounds," Marina President and CEO Michael French said in a statement. "Further, we now have in vivo proof of concept across our entire nucleic acid-based therapeutic platform demonstrating the ability to silence gene targets through either RNA interference or translational blocking, or via a microRNA mimetic, and, in the case of these data, to up-regulate gene targets via a microRNA antagonist.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.